One of the most basic ideas that goes along with the stock market is buy low and sell high. Although this advice is overly obvious, many new investors will do the exact opposite when trading stocks. Inexperienced investors have the tendency to buy stocks that have been performing the best recently. This may be caused by certain factors such as not looking into the underlying fundamentals or just hoping that the stock will continue to rise. Rookie investors may also make the error of holding onto shares that continue to drop in value. Instead of cutting the loser loose, they hold off with the hope that eventually the stock will at least get back to the breakeven point.
Following recent trading activity, we note that VanEck Vectors Pharmaceutical ETF (ASX:PPH) has seen a move of -0.4596527% since the open. The prior close was 58.47 and the one month high price is currently 61.72.
Traders using technical analysis may be employing moving average indicators to assist with gauging a certain market move or to indicate its strength. Many traders will rely on the EMA or Exponential Moving Average to accomplish this. Checking on some recent levels for VanEck Vectors Pharmaceutical ETF (ASX:PPH), we can see that the 10 day EMA is 59.244637, the 20 day is 59.62514, and the 30 day is 59.815044. Pulling back a bit, we note that the 100 day EMA is 59.761715, the 50 day is 59.91754, and the 200 day EMA is 59.733303.
After a recent check, we see that the Bull Bear Power reading is -1.7364243. Moving to some volatility readings, we see that the current value is 1.0609171. Looking out for the week, volatility is 0.8203028. For the previous month, volatility is at 0.8797383. Investors often track volatility across sectors to compare with the overall volatility in the market.
A good way for investors to understand stock price movements is to look at how it has performed at various intervals in the past. Tracking shares of VanEck Vectors Pharmaceutical ETF (ASX:PPH), we see that the most recent close price was 58.47
Prior week: -2.4670777
Prior month: -2.6941626
Last 6 months:-6.4139476
Last 3 months: 1.8805503
Traders use pivot point analysis to help determine key levels where a stock price may react. Tracking these turn around levels may help the trader while attempting stock analysis. Looking at some current one month pivots, we note that the Fibonacci pivot is 60.04 while the Fibonacci support 1 pivot is 59.48228, and the Fibonacci support 2 is 59.13772. Checking on the one month Woodie pivot, we note the level at 59.99. The Woodie support 1 pivot is 59.24, and the Woodie resistance 1 pivot is 60.7.
Investors might be looking around every corner when analyzing shares of VanEck Vectors Pharmaceutical ETF (ASX:PPH). Many investors will closely track a stock when it nears a major historical high or low point. Let’s take a quick peek at some major historical highs and lows for the stock:
All time high: 74.97
All time low: 24.64
52 week high: 64.9
52 week low: 52.39
6 month high: 63.29
6 month low: 52.39
3 month high: 61.72
3 month low: 56.57
One month high: 61.72
One month low: 58.44
Investors might be looking to find some bargains to add to the portfolio as we move closer towards the end of the year. Maybe some of the earlier portfolio picks don’t look as promising as they did a few months ago. There might also be a few names that have fallen off a cliff and do not look they will be returning to previous levels. Investors may be searching for a few overlooked stocks that the rest of the investing community has passed on for whatever reason. Nobody knows for sure what the next couple of quarters have in store. As earnings season kicks off, investors will be closely following the companies that manage to beat expectations by a wide margin.
Shifting the technical focus to Keltner Channels, we see that the 20 day upper envelope is 59.883904. The 20 day lower envelope is currently 59.36638. Traders may be watching for a breakthrough of the higher or lower Keltner bands.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.